Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Payables: 2019-2024

Historic Payables for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $16.4 million.

  • Silence Therapeutics' Payables rose 191.64% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.5 million, marking a year-over-year increase of 288.79%. This contributed to the annual value of $16.4 million for FY2024, which is 5.55% up from last year.
  • Latest data reveals that Silence Therapeutics reported Payables of $16.4 million as of FY2024, which was up 5.55% from $15.5 million recorded in FY2023.
  • Silence Therapeutics' 5-year Payables high stood at $16.4 million for FY2024, and its period low was $10.5 million during FY2020.
  • Over the past 3 years, Silence Therapeutics' median Payables value was $15.6 million (recorded in 2022), while the average stood at $15.9 million.
  • In the last 5 years, Silence Therapeutics' Payables skyrocketed by 41.03% in 2021 and then fell by 0.62% in 2023.
  • Over the past 5 years, Silence Therapeutics' Payables (Yearly) stood at $10.5 million in 2020, then surged by 41.03% to $14.8 million in 2021, then increased by 5.38% to $15.6 million in 2022, then declined by 0.62% to $15.5 million in 2023, then grew by 5.55% to $16.4 million in 2024.